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way [6]. Nonetheless, at the present time, mutation of KRAS is 
the only negative molecular marker to anti-EGFR mAbs treat-
ment [2, 5]. Recently, a somatic mutation of the EGFR kinase 
domain was initially reported in lung cancer and later in colorec-
tal carcinomas. In lung cancer, mutations in the EGFR gene 
are associated with a high response rate to EGFR tyrosine ki-
nase inhibitors and are prognostic for a favorable outcome.
In this paper, the authors reported the incidence of the EGFR 
mutation in colorectal carcinomas as 22.41%. The incidence 
was higher than reports in Western countries, and the EGFR 
mutation was increased in earlier stages and in the absence of 
lymph node metastasis. Also exon 20 was the only mutation 
site, which is different from reports in Japan (mutations in exon 
19 and 20). The EGFR mutation state may be an important 
determinant in the resistance to anti-EGFR mAbs treatment. 
To address this, larger studies are needed, and hopefully it will 
be another predictive marker for anti-EGFR mAbs therapy in 
mCRC [7].
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Expression of epidermal growth factor receptor (EGFR) was 
found in 60-75% of colorectal carcinomas. Based on this, many 
studies have demonstrated the efficiency of monoclonal Abs 
(mAbs) in targeting the EGFR, such as cetuximab and panitu-
mumab, in metastatic colorectal cancer (mCRC) patients. Ad-
dition of cetuximab to irinotecan-based chemotherapy signifi-
cantly improved the response rate and the progression-free sur-
vival (PFS) when compared with Cetuximab mAb alone (22.9% 
vs. 10.8% and 4.1 vs. 1.5 months, respectively) [1].
Van Cutsem et al. [2, 3] reported that in chemonaive mCRC 
patients, the addition of anti-EGFR to irinotecan-based chemo-
therapy led to an 8.2% increase in the objective response (46.8% 
vs. 38.4%), a 0.9-month increase in the progression free survival 
(PFS) (8.9 vs. 8 months) and a 1.3-month increase in the overall 
survival (19.9 vs. 18.6 months). Initially, the use of anti-EGFR 
mAbs was restricted to mCRC patients with expression of EGFR 
that was detectable using immunohistochemistry. However, due 
to the lack of immunohistochemistry predictive value and the 
variable clinical response, more reliable predictive markers of 
the response to anti-EGFR mAbs are needed [4].
Two types of molecular predictive markers have been inves-
tigated. The first is somatic mutations in EGFR pathway effec-
tors, such as RAS-RAF-MAPK and PI3K-Akt-PTEN. Ampli-
fication of EGFR and overexpression of EGFR ligands are as-
sociated with sensitivity to anti-EGFR mAbs, but the mutations 
of BRAF and PIK3A and the loss of PTEN expression are as-
sociated with resistance to anti-EGFR mAbs [2, 5]. The second 
is germline polymorphisms of genes involved in the EGFR path-
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